Welcome to our dedicated page for Know Labs SEC filings (Ticker: KNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive associated with the historical ticker KNW provides a detailed record of Know Labs, Inc.’s regulatory disclosures as it developed radio frequency spectroscopy and RFDS technology and later transformed into USBC, Inc. Investors can review Forms 10‑K and 10‑Q for information on the company’s RFDS‑based diagnostic platform, its plans for a non‑invasive glucose monitor that will require FDA clearance, and the role of Know Labs Technology Licensing (KTL) in licensing RFDS and the e‑RFDS© digital watermark to external partners.
More recent Form 8‑K filings document key corporate events. An 8‑K dated February 18, 2025 describes a 1‑for‑40 reverse stock split and the company’s move to trading on the OTC Pink Market under KNWN while appealing NYSE American delisting proceedings related to bid price requirements. Subsequent 8‑Ks filed in July and August 2025 outline the Securities Purchase Agreement with Goldeneye 1995 LLC, the bridge financing arrangement, shareholder approvals to increase authorized common stock and amend the 2021 Equity Incentive Plan, and the closing of a private placement in which the buyer acquired approximately 81% of the company’s common stock.
These filings also explain how preferred stock series were converted or redeemed, how legacy debt instruments were repaid or satisfied with cash and common stock, and how the company adopted indemnification agreements for directors and officers. An 8‑K filed on August 15, 2025 reports the completion of the name change to USBC, Inc. and ticker change to USBC on the NYSE American, as well as the change of principal executive offices to Reno, Nevada.
On Stock Titan, users can access these historical KNW filings as they were submitted to EDGAR and use AI‑powered summaries to interpret complex sections. This includes quickly understanding material contracts, capital structure changes, reverse stock split mechanics, change‑of‑control terms, and ongoing risk disclosures related to the company’s RFDS technology, licensing activities, and later digital asset‑focused strategies.
USBC, Inc. filed a Form D reporting a completed exempt equity offering under Rule 506(b). The filing states a total offering amount of $119,868,025, with the entire amount sold and $0 remaining. The issuer is a Nevada corporation with principal office in Reno. The offering closed with one investor reported. Cohen & Company Securities, LLC received a closing fee equal to 1% of post-closing common stock: 3,909,549 shares at $0.335 per share totaling $1,309,699 (recorded as sales commissions). The issuer indicates no proceeds were paid to listed officers, directors or promoters.
Linda Jenkinson, a director of the issuer, was granted an option to purchase 4,760,000 shares of the issuer's common stock on 08/06/2025 under the 2021 Equity Incentive Plan. The option has an exercise price of $2.45 per share and an expiration date of 08/06/2035. The option vests 25% on the one-year anniversary of the grant date, with the remainder vesting in quarterly installments over the following three years. The Form 4 was signed on 08/15/2025.
Linda Jenkinson filed an Initial Statement on Form 3 reporting her relationship to the issuer as a Director of USBC, Inc. The filing shows the date of event as 08/06/2025 and is signed on 08/15/2025. The form states that no securities are beneficially owned by the reporting person. The filing lists a Reno, NV address for the reporting person and indicates the form was filed by one reporting person.
Chapman Kirk, Chief Operating Officer and Director of USBC, Inc. (USBC), was granted an option on August 6, 2025 to purchase 7,140,000 shares of the company's common stock at an exercise price of $2.45 per share. The option vests 25% on the one-year anniversary of the grant and then in quarterly installments over the following three years, and is exercisable through August 6, 2035. The Form 4 was signed on August 15, 2025.
Initial Form 3 filed by Kirk Chapman, Chief Operating Officer of USBC, Inc. The report states that the reporting person does not beneficially own any securities of the issuer. The filing identifies the reporting person's role as Officer and Director and confirms the Form 3 is an initial ownership disclosure required under Section 16.
USBC, Inc., formerly known as Know Labs, Inc., reported several corporate changes and governance updates. The company adopted a new form of indemnification agreement for its directors and officers, providing indemnification to the fullest extent permitted by law and its governing documents, including advancement of expenses with reimbursement if indemnification is later found unwarranted. The company also maintains a directors’ and officers’ liability insurance policy covering certain securities law liabilities.
The company completed a change of its corporate name to USBC, Inc. and updated its trading symbol to “USBC” on the NYSE American, each effective August 15, 2025. In addition, the principal executive offices were relocated to Reno, Nevada.
Know Labs, Inc. issued 357,815,000 shares of its common stock to Goldeneye 1995 LLC in a private placement under a Securities Purchase Agreement dated June 5, 2025, with the closing on August 6, 2025. Goldeneye paid $15,000,000 in cash and 1,000 Bitcoin for the shares at a per-share price of $0.335. The issuance results in Goldeneye and Robert Gregory Kidd each being the beneficial owner of 357,815,000 shares, representing approximately 93.1% of the class based on 384,234,130 shares reported outstanding.
Following the closing, the company appointed Robert Gregory Kidd as Chief Executive Officer, President and Chairman and named Linda Jenkinson as Vice Chair. The filing discloses Voting and Support Agreements under which certain stockholders holding approximately 37% of the voting power agreed to vote to approve the Purchase Agreement. The Reporting Persons state they currently have no other specific plans beyond those disclosed, while reserving the right to buy, sell or transfer shares in the future.
On August 6, 2025 Know Labs issued 357,815,000 shares of common stock to Goldeneye 1995 LLC in a private placement at $0.335 per share, disclosed on an initial Form 3. The filing names Robert Gregory Kidd as sole owner and manager of the reporting entity and states he has voting control and investment discretion over the shares.
Know Labs filed a Form 3 reporting that Robert Gregory Kidd disclosed beneficial ownership of 357,815,000 common shares held indirectly through Goldeneye 1995 LLC. The shares were issued in a private placement on 08/06/2025 at a purchase price of $0.335 per share. Kidd is identified as a Director, an Officer (CEO, President, Chairman) and a 10% owner, and he is the sole owner and manager of Goldeneye with voting control and investment discretion over the shares.
On August 6, 2025, Kitty B. Payne, an officer of Know Labs, Inc. (KNW), was granted an option to purchase 1,790,000 shares of the company's common stock at an exercise price of $2.45 per share under the 2021 Equity Incentive Plan. The option vests 25% on the one-year anniversary of the grant and then in quarterly installments over the following three years, tying vesting to continued service. The grant is reported as a direct ownership interest and the option shows an expiration date of August 6, 2035, indicating a 10-year term from the grant date. The Form 4 reports the transaction as an acquisition of derivative securities through the company plan.
FAQ
What is the current stock price of Know Labs (KNW)?
What is the market cap of Know Labs (KNW)?
